Navigation Links
Cerimon to Conduct a Proof of Concept Study for Basiliximab for Noninfectious Uveitis, a Potentially Sight-Threatening Inflammation of the Eye
Date:3/10/2008

SOUTH SAN FRANCISCO, Calif., March 10 /PRNewswire/ -- Cerimon Pharmaceuticals announced today it has entered into an agreement with Novartis Pharma AG to conduct a proof of concept study for Simulect(R) (basiliximab) for the treatment of noninfectious uveitis, an autoimmune inflammation of the eye's internal structures. Uveitis can cause severe visual impairment and accounts for an estimated 10 percent of blindness cases in the Western World. Basiliximab is a monoclonal antibody that selectively blocks the interleukin-2 (IL-2) receptor. This mechanism of action provides highly targeted inhibition of the T-lymphocyte activation that is involved in serious immune-related diseases.

"There is a significant need for new effective therapies for the treatment of noninfectious uveitis patients. Part of Cerimon's overall strategy is to expand our basiliximab development program into other autoimmune diseases where there is significant medical need," commented Paul Sekhri, President and CEO of Cerimon Pharmaceuticals. "The agreement also exemplifies our strong relationship with Novartis, one of the leading worldwide pharmaceutical companies."

Dr. Daniel Levitt, Cerimon's Executive Vice President of Research and Development, stated, "Based on the mechanism of action of basiliximab, we believe this compound is well-suited to the treatment of noninfectious uveitis, a chronic eye inflammation that can lead to complications such as glaucoma, cataract, and vision loss. Basiliximab has the potential to significantly improve the quality of life for this group of uveitis patients and reduce adverse events often associated with current treatments that include corticosteroids and other immunosuppressive therapies."

In February 2006, Cerimon licensed basiliximab from Novartis for the treatment of Inflammatory Bowel Disease (IBD). In April 2007, Cerimon initiated a Phase IIb clinical study, titled ARREST UC-1 (Achieve Remission & Reduce or Eliminate Steroid Therapy in Ulcerative Colitis), for the treatment of ulcerative colitis, a common type of IBD.

About Autoimmune Uveitis

Uveitis is an inflammation of the internal structures of the eye. There are two types of uveitis, infectious and noninfectious. Noninfectious uveitis is believed to be the result of an autoimmune disorder. Autoimmune uveitis affects approximately 175,000 people in the United States and can lead to blindness. Current treatments include topical and oral corticosteroids and immunosuppressive drugs; however, these generally have limited success and can lead to adverse effects.

About Cerimon Pharmaceuticals

Cerimon Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for autoimmune diseases, inflammation, and pain. Cerimon believes these new treatment options will enable physicians specialized in treating these conditions to further improve the lives of their patients.

Cerimon currently has two drugs in development. Simulect(R) (basiliximab) entered a Phase IIb study for moderate-to-severe ulcerative colitis in the April 2007. In late fourth quarter 2007, Cerimon's topical patch formulation of diclofenac entered two Phase II/III clinical studies for the treatment of acute musculoskeletal pain.

The Company is well-financed, having closed a $70 million Series A financing in late 2005 with premier investors including MPM, Nomura Phase4 Ventures, and OrbiMed Advisors.

For more information on Cerimon, please visit the Company's website at http://www.cerimon.com.


'/>"/>
SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. SpineMark, NeuStrategy Partner to Conduct Nations First Spine COE Survey(TM)
2. Nursing Home Workers Strike Over Employer Misconduct
3. Parents Identify Health Topics They Want Doctors to Discuss with Kids - New Research for University of Michigan Conducted by Knowledge Networks
4. inVentiv Health to Announce Fourth Quarter and Full Year 2007 Results and Conduct Conference Call on Thursday, February 28th
5. The Willie Gary Law Firm Files $1 Billion Lawsuit Against Durham County LME, Wake County LME, Five County LME, Mecklenberg County LME and Value Options, Inc. for Negligent and Intentional Misconduct Against Mental Health Agency
6. Doctors Group Sues Texas Medical Board for Misconduct; Cites Institutional Culture of Retaliation & Intimidation
7. Heavy drinking, conduct disorder linked to high-risk sexual behavior
8. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
9. Novel semiconductor structure bends light wrong way -- the right direction for many applications
10. CareTech Solutions Executive to Conduct Presentation on Creating a Healthy Revenue Cycle at AHIMA Convention and Exhibit
11. inVentiv Health to Announce Third Quarter Results and Conduct Conference Call on Wednesday, November 7, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Giving patients with ... the emergency room, fewer hospital admissions, and better blood pressure and glycemic control, ... finds. The study can be found here . , The study comes ...
(Date:2/22/2017)... ... February 22, 2017 , ... Doctors on Liens is ... esteemed ophthalmologist, Dr. Steven H. Rauchman, practicing at North Valley Eye Medical Group ... product liability, premise liability and other personal injury cases. These injuries have a ...
(Date:2/22/2017)... D.C. (PRWEB) , ... February 22, 2017 , ... ... being celebrated throughout the country today, as organizations, advocates, and individuals join together ... detection and treatment access to ultimately save lives. , “Today we mark a ...
(Date:2/22/2017)... ... February 22, 2017 , ... Bellus Medical, a leader in ... the delivery of Platelet Rich Plasma (PRP). PRP systems are used by physicians ... tissue synthesis and provide a faster and more efficient healing process. There are ...
(Date:2/22/2017)... ... February 22, 2017 , ... The SeniorCare Investor will host ... —on Thursday, February 23, 2017, at 1:00 PM ET. A recording of the webinar ... the Interactive Webinar Series. , If you want to find out what really happened ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... Feb. 22, 2017 a condition where ... abdominal wall due to weak abdominal wall. Hernia ... hernia, incisional hernia, femoral hernia, umbilical hernia, and ... The hernia surgeries are performed using a mesh, ... help fixation devices. Among the available options, open ...
(Date:2/22/2017)... Feb. 22, 2017  Ultra Clean Holdings, Inc. ... critical systems and subsystems for the semiconductor capital ... today reported its financial results for the fourth ... "2016 was a year of extraordinary ... reached record highs and together with continued focus ...
(Date:2/22/2017)... YORK , Feb. 22, 2017 ... the myocardial infarction partnering deals and agreements entered ... Read the full report: http://www.reportlinker.com/p03605670-summary/view-report.html ... report provides understanding and access to partnering deals ... healthcare companies. - Trends in partnering ...
Breaking Medicine Technology: